Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Charles River Laboratories | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Charles River Laboratories

RMS segment sales were up, while PCS segment sales declined

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories

4Q Revenues: $291.0 million (+3%)

4Q Earnings: $27.1 million (loss of $342.4 million 4Q10)

FY Revenues: $1.1 billion (+1%)

FY Earnings: $115.5 million (loss of $334.1 million FY10)

Comments: Sales for the Research Models and Services (RMS) segment were $182.4 million in 4Q11 (+8%), and $705.4 million for the year (+6%). Sales from the Preclinical Services (PCS) segment in the quarter were $108.5 million (-4%), due to shorter term, less complex studies, as well as fewer GLP safety assessment studies. For the year PCS sales were $437.2 million (-6%). In 4Q10 results included non-cash goodwill and asset impairments of $395.0 million, and for the year, results included a $30.0 million fee related to the termination of a proposed acquisition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters